Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $15 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $15 price target.
byBenzinga Newsdesk
March 14, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $15 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Century Aluminum Reaches Agreement On New Three-Year Mt. Holly Power Contract; Will Begin On January 1, 2024 And Run Through December 2026; Contract Provides For 295MW Of Electric Power, Allowing The Smelter To Continue Operating At Its Current Capaci…

By Happy Mohamed
October 23, 4:14 PM
Century Aluminum of South Carolina (CASC), a wholly-owned subsidiary of Century Aluminum Company (NASDAQ:CENX), announced today it has finalized, and received all necessary approvals for, a new, three-year power contract

CENX